XENETIC BIOSCIENCES, INC. Impairment of Long-Lived Assets Held-for-use
XENETIC BIOSCIENCES, INC. (XBIO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2021-03-16
- XENETIC BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2020 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2019 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2018 was $0.00.
- XENETIC BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2017 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-16 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-16 |
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-30 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-31 |
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |